Orozco-Mera Javier, Montoya-Gómez Alejandro, Lopes Daiana Silva, Jiménez-Charris Eliécer
Grupo de Nutrición, Facultad de Salud, Universidad del Valle, Cali, Colombia.
Department of Neurosurgery, Clínica Imbanaco, Cali, Colombia.
J Venom Anim Toxins Incl Trop Dis. 2024 Sep 16;30:e20240015. doi: 10.1590/1678-9199-JVATITD-2024-0015. eCollection 2024.
Glioblastoma (GB) is the most common type of malignant tumor of the central nervous system, responsible for significant morbidity and with a 5-year overall relative survival of only 6.8%. Without advances in treatment in the last twenty years, the standard of care continues to be maximum safe resection, Temozolomide (TMZ), and radiotherapy. Many new trials are ongoing, and despite showing increased progression-free survival, these trials did not improve overall survival. They did not consider the adverse effects of these therapies. Therefore, an increasing number of bioprospecting studies have used snake venom molecules to search for new strategies to attack GB selectively without producing side effects. The present review aims to describe GB characteristics and current and new approaches for treatment considering their side effects. Besides, we focused on the antitumoral activity of snake venom proteins from the Viperidae family against GB, exploring the potential for drug design based on and studies. This review followed the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines. In January 2024, a systematic search was performed in the PubMed, EMBASE, and Web of Science databases from January 2000 to December 2023. Search terms were selected based on the population/exposure/outcome (PEO) framework and combined using Boolean operators ("AND", "OR"). The search strategy used these terms: glioblastoma, glioma, high-grade glioma, WHO IV glioma, brain cancer, snake venom, Viperidae, and bioprospection. We identified 10 and studies with whole and isolated proteins from Viperidae venom that could have antitumor activity against glioblastoma. Studies in bioprospecting exploring the advantage of snake venom proteins against GB deserve to be investigated due to their high specificity, small size, inherent bioactivity, and few side effects to cross the blood-brain barrier (BBB) to reach the tumor microenvironment.
胶质母细胞瘤(GB)是中枢神经系统最常见的恶性肿瘤类型,具有较高的发病率,5年总相对生存率仅为6.8%。在过去二十年中治疗方法没有进展,目前的标准治疗方案仍然是最大程度的安全切除、替莫唑胺(TMZ)和放疗。许多新的试验正在进行,尽管显示无进展生存期有所延长,但这些试验并未改善总生存期。它们没有考虑这些疗法的不良反应。因此,越来越多的生物勘探研究使用蛇毒分子来寻找选择性攻击GB而不产生副作用的新策略。本综述旨在描述GB的特征以及考虑到副作用的当前和新的治疗方法。此外,我们重点关注蝰蛇科蛇毒蛋白对GB的抗肿瘤活性,基于[具体研究]探索药物设计的潜力。本综述遵循系统评价和Meta分析的首选报告项目(PRISMA)指南。2024年1月,在PubMed、EMBASE和Web of Science数据库中对2000年1月至2023年12月进行了系统检索。搜索词基于人群/暴露/结局(PEO)框架进行选择,并使用布尔运算符(“AND”、“OR”)进行组合。搜索策略使用了以下术语:胶质母细胞瘤、神经胶质瘤、高级别神经胶质瘤、世界卫生组织IV级神经胶质瘤、脑癌、蛇毒、蝰蛇科和生物勘探。我们鉴定出10项[具体研究],这些研究涉及蝰蛇科毒液的完整蛋白和分离蛋白,它们可能对胶质母细胞瘤具有抗肿瘤活性。由于蛇毒蛋白具有高特异性、小尺寸、固有生物活性以及穿越血脑屏障(BBB)到达肿瘤微环境的副作用少等优点,探索蛇毒蛋白对抗GB优势的生物勘探研究值得深入研究。